August 4, 2022
|
Outlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology Conference
|
|
July 5, 2022
|
Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note
|
|
June 14, 2022
|
Outlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010
|
|
May 31, 2022
|
Outlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMD
|
|
May 18, 2022
|
Outlook Therapeutics to Present at the H.C. Wainwright Global Investment Conference
|
|
May 13, 2022
|
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update
|
|
May 10, 2022
|
Outlook Therapeutics to Participate in Retina World Congress 2022
|
|
May 9, 2022
|
Outlook Therapeutics to Participate at the Virtual Investor 2022 CEO Spotlight
|
|
April 22, 2022
|
BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics
|
|
April 5, 2022
|
Outlook Therapeutics to Present at Wet AMD and DME Drug Development Summit
|
|